Wohoooooo_老虎社区_美港股上老虎

2021-09-24

Wohoooooo

Novavax surged over 10% in early trading<blockquote>Novavax 早盘交易飙升超过 10%</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":863790842,"tweetId":"863790842","gmtCreate":1632433202886,"gmtModify":1632728523593,"author":{"id":3582276393501319,"idStr":"3582276393501319","authorId":3582276393501319,"authorIdStr":"3582276393501319","name":"ElonTong","avatar":"https://static.tigerbbs.com/319eee711bf7ef88f2dfca26fa17a541","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":14,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Wohoooooo</p></body></html>","htmlText":"<html><head></head><body><p>Wohoooooo</p></body></html>","text":"Wohoooooo","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/863790842","repostId":1136461867,"repostType":4,"repost":{"id":"1136461867","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1632405237,"share":"https://www.laohu8.com/m/news/1136461867?lang=zh_CN&edition=full","pubTime":"2021-09-23 21:53","market":"us","language":"en","title":"Novavax surged over 10% in early trading<blockquote>Novavax 早盘交易飙升超过 10%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1136461867","media":"Tiger Newspress","summary":"(Sept 23) Novavax surged over 10% in early trading. Novavax Announce Submission to World Health Orga","content":"<p>(Sept 23)&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> </b>surged over 10% in early trading.&nbsp;Novavax Announce Submission to World Health Organization for Emergency Use Listing of Novavax' COVID-19 Vaccine.</p><p><blockquote>（9月23日）<b><a href=\"https://laohu8.com/S/NVAX\">诺瓦瓦克斯</a></b>早盘飙升超过10%。诺瓦瓦克斯宣布向世界卫生组织提交诺瓦瓦克斯新冠肺炎疫苗的紧急使用清单。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/38fe74a02950ee20c0a498be55a8e0a4\" tg-width=\"958\" tg-height=\"563\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, with its partner, Serum Institute of India Pvt. Ltd. (SII), today announced a regulatory submission to the World Health Organization (WHO) for emergency use listing (EUL) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant. The submission to WHO is based on the companies' previous regulatory submission to the Drugs Controller General ofIndia(DCGI).</p><p><blockquote>致力于开发和商业化用于严重传染病的下一代疫苗的生物技术公司 Novavax, Inc.（纳斯达克股票代码：NVAX）及其合作伙伴 Serum Institute of India Pvt.Ltd. (SII) 今天宣布向世界卫生组织 (WHO) 提交 Novavax 基于 Matrix-M 的重组纳米颗粒蛋白 COVID-19 候选疫苗的紧急使用上市 (EUL)™佐剂。向世卫组织提交的材料是基于这些公司之前向印度药品控制总局 (DCGI) 提交的监管材料。</blockquote></p><p> \"Today's submission of our protein-based COVID-19 vaccine to WHO for emergency use listing is a significant step on the path to accelerating access and more equitable distribution to countries in great need around the world,\" saidStanley C. Erck, President and Chief Executive Officer, Novavax. \"It represents another major milestone in Novavax' transformation into a commercial global vaccine company and reinforces the value of global collaboration and need for multiple approaches to help control the pandemic.\"</p><p><blockquote>总裁兼首席执行官斯坦利·C·埃克 (Stanley C. Erck) 表示：“今天向世界卫生组织提交我们的基于蛋白质的 COVID-19 疫苗进行紧急使用清单，这是加快向世界各地急需疫苗的国家提供和更公平地分发疫苗的重要一步。” ，Novavax。“这代表着 Novavax 转型为商业全球疫苗公司的又一个重要里程碑，并强化了全球合作的价值以及采取多种方法帮助控制流行病的必要性。”</blockquote></p><p> The grant of EUL by the WHO is a prerequisite for exports to numerous countries participating in the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies. In addition to the submission for WHO EUL, SII and Novavax last month completed the submission of modules required by regulatory agencies inIndia,Indonesiaandthe Philippinesfor the initiation of review of the vaccine, including preclinical, clinical, and chemistry, manufacturing and controls (CMC) data.</p><p><blockquote>世卫组织授予EUL是向许多参与新冠疫苗保障机制的国家出口疫苗的先决条件，该组织的建立是为了向参与国和经济体公平地分配和分发疫苗。除了提交 WHO EUL 外，SII 和 Novavax 上个月还完成了印度、印度尼西亚和菲律宾监管机构启动疫苗审查所需模块的提交，包括临床前、临床以及化学、制造和控制 (CMC) 数据。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax surged over 10% in early trading<blockquote>Novavax 早盘交易飙升超过 10%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax surged over 10% in early trading<blockquote>Novavax 早盘交易飙升超过 10%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-09-23 21:53</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(Sept 23)&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> </b>surged over 10% in early trading.&nbsp;Novavax Announce Submission to World Health Organization for Emergency Use Listing of Novavax' COVID-19 Vaccine.</p><p><blockquote>（9月23日）<b><a href=\"https://laohu8.com/S/NVAX\">诺瓦瓦克斯</a></b>早盘飙升超过10%。诺瓦瓦克斯宣布向世界卫生组织提交诺瓦瓦克斯新冠肺炎疫苗的紧急使用清单。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/38fe74a02950ee20c0a498be55a8e0a4\" tg-width=\"958\" tg-height=\"563\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, with its partner, Serum Institute of India Pvt. Ltd. (SII), today announced a regulatory submission to the World Health Organization (WHO) for emergency use listing (EUL) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant. The submission to WHO is based on the companies' previous regulatory submission to the Drugs Controller General ofIndia(DCGI).</p><p><blockquote>致力于开发和商业化用于严重传染病的下一代疫苗的生物技术公司 Novavax, Inc.（纳斯达克股票代码：NVAX）及其合作伙伴 Serum Institute of India Pvt.Ltd. (SII) 今天宣布向世界卫生组织 (WHO) 提交 Novavax 基于 Matrix-M 的重组纳米颗粒蛋白 COVID-19 候选疫苗的紧急使用上市 (EUL)™佐剂。向世卫组织提交的材料是基于这些公司之前向印度药品控制总局 (DCGI) 提交的监管材料。</blockquote></p><p> \"Today's submission of our protein-based COVID-19 vaccine to WHO for emergency use listing is a significant step on the path to accelerating access and more equitable distribution to countries in great need around the world,\" saidStanley C. Erck, President and Chief Executive Officer, Novavax. \"It represents another major milestone in Novavax' transformation into a commercial global vaccine company and reinforces the value of global collaboration and need for multiple approaches to help control the pandemic.\"</p><p><blockquote>总裁兼首席执行官斯坦利·C·埃克 (Stanley C. Erck) 表示：“今天向世界卫生组织提交我们的基于蛋白质的 COVID-19 疫苗进行紧急使用清单，这是加快向世界各地急需疫苗的国家提供和更公平地分发疫苗的重要一步。” ，Novavax。“这代表着 Novavax 转型为商业全球疫苗公司的又一个重要里程碑，并强化了全球合作的价值以及采取多种方法帮助控制流行病的必要性。”</blockquote></p><p> The grant of EUL by the WHO is a prerequisite for exports to numerous countries participating in the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies. In addition to the submission for WHO EUL, SII and Novavax last month completed the submission of modules required by regulatory agencies inIndia,Indonesiaandthe Philippinesfor the initiation of review of the vaccine, including preclinical, clinical, and chemistry, manufacturing and controls (CMC) data.</p><p><blockquote>世卫组织授予EUL是向许多参与新冠疫苗保障机制的国家出口疫苗的先决条件，该组织的建立是为了向参与国和经济体公平地分配和分发疫苗。除了提交 WHO EUL 外，SII 和 Novavax 上个月还完成了印度、印度尼西亚和菲律宾监管机构启动疫苗审查所需模块的提交，包括临床前、临床以及化学、制造和控制 (CMC) 数据。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136461867","content_text":"(Sept 23) Novavax surged over 10% in early trading. Novavax Announce Submission to World Health Organization for Emergency Use Listing of Novavax' COVID-19 Vaccine.\n\nNovavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, with its partner, Serum Institute of India Pvt. Ltd. (SII), today announced a regulatory submission to the World Health Organization (WHO) for emergency use listing (EUL) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant. The submission to WHO is based on the companies' previous regulatory submission to the Drugs Controller General ofIndia(DCGI).\n\"Today's submission of our protein-based COVID-19 vaccine to WHO for emergency use listing is a significant step on the path to accelerating access and more equitable distribution to countries in great need around the world,\" saidStanley C. Erck, President and Chief Executive Officer, Novavax. \"It represents another major milestone in Novavax' transformation into a commercial global vaccine company and reinforces the value of global collaboration and need for multiple approaches to help control the pandemic.\"\nThe grant of EUL by the WHO is a prerequisite for exports to numerous countries participating in the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies. In addition to the submission for WHO EUL, SII and Novavax last month completed the submission of modules required by regulatory agencies inIndia,Indonesiaandthe Philippinesfor the initiation of review of the vaccine, including preclinical, clinical, and chemistry, manufacturing and controls (CMC) data.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":2133,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":9,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/863790842"}